Front. Pharmacol.Frontiers in PharmacologyFront. Pharmacol.1663-9812Frontiers Media S.A.147843710.3389/fphar.2025.1478437PharmacologyCorrectionCorrigendum: Empagliflozin alleviates hepatic steatosis by activating the AMPK-TET2-autophagy pathway in vivo and in vitroLi et al.10.3389/fphar.2025.1478437LiTingFangTingXuLinxinLiuXiangyangLiXiaoyuXueMeiYuXiaochenSunBei*ChenLiming*NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital and Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China
Edited and reviewed by:Stefano Fiorucci, University of Perugia, Italy
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A Corrigendum on Empagliflozin alleviates hepatic steatosis by activating the AMPK-TET2-autophagy pathway in vivo and in vitro by Li T, Fang T, Xu L, Liu X, Li X, Xue M, Yu X, Sun B and Chen L (2021). Front. Pharmacol. 11:622153. doi: 10.3389/fphar.2020.622153empagliflozinautophagydiabetesmetabolic associated fatty liver diseaselipid accumulationten-eleven translocation 2section-at-acceptanceGastrointestinal and Hepatic Pharmacology
In the published article, there was an error in Figure 3 as published. The merge of the PA+HG+Empa group (Figure 3D) was presented correctly, but the DAPI of PA + HG + Empa group (Figure 3D) was presented incorrectly. When the authors were preparing the DAPI of PA + HG + Empa group in Figure 3D, they mistakenly copied the image of the DAPI of NC group in Figure 5D. The corrected Figure 3 and its caption appear below.
Empagliflozin ameliorates lipid accumulation and activates autophagy and the AMPK-TET2 signaling in HL7702 cells treated with PA and HG (A–J) HL7702 cells were treated with or without PA and HG, with or without empagliflozin (A) Representative images of Oil Red O staining and (B) quantitative analysis of TGs. Scale bar represents 30 μm. Immunofluorescence of (C) TET2 and (D) p62 in HL7702 cells. Scale bars represent 30 μm (C) and 100 μm (D), respectively, (E) Western blot analyses of ATG5, Beclin-1, p62, TET2, p-AMPK, and AMPK with β-actin as a loading control and (F–J) densitometric analyses of band intensities normalized to β-actin (K–O) HL7702 cells were treated with or without PA and HG, with or without empagliflozin, in the presence or absence of 3-MA (K) Western blot analyses of Beclin-1 and p62 with β-actin as a loading control and (L, M) densitometric analyses of band intensities normalized to β-actin (N) Representative images of Oil Red O staining and (O) quantitative analyses of TGs. Data in (B, F–J, L, M, and O) are presented as means ± SEM from three independent experiments. Empa, empagliflozin; HG, high glucose; NC, negative control group; PA, palmitic acid; TG, triglyceride; 3-MA, 3-methyladenine. *p < 0.05, **p < 0.01, ***p < 0.001.
In the published article, there was an error in Figure 4 as published. The authors incorrectly used the image of the PA + HG + Empa group while preparing the image of the PA + HG + AICAR group (Figure 4A). The corrected Figure 4 and its caption appear below.
The increase in TET2 and autophagy and reduction in lipid accumulation by empagliflozin are dependent on AMPK activation. HL7702 cells were treated with or without PA and HG, with or without empagliflozin, in the presence or absence of AICAR or compound C (A) Representative images of oil red O staining and (B) quantitative analysis of TGs. Scale bar represents 30 μm (C, I) Western blot analyses of p-AMPK, AMPK, TET2, ATG5, Beclin-1, and p62 with β-actin as a loading control and (D–H, J–N) densitometric analyses of band intensities normalized to β-actin. Data in (B, D–H, J–N) are presented as means ± SEM from three independent experiments. Empa, empagliflozin; HG, high glucose; NC, negative control group; ns, not significant; PA, palmitic acid; TG, triglyceride. *p < 0.05, **p < 0.01, ***p < 0.001.
In the published article, there was an error in Supplementary Data Sheet 1. An error was found in the western blot of the β-actin protein panel in Supplementary Figure 5A. The corrected Supplementary Figure 5 can be found in the Supplementary Material link of the original article.
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.